カンザス州における転移性癌の臨床試験
カンザス州内の拠点で、転移性癌に関する15件の研究が参加者を募集しています。
カンザス州内の都市
公式研究テキスト（英語）
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- University of Kansas Cancer Center, Fairway
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT07562152A Study of ASP3082 in Adults With Advanced Solid Tumors
- University of Kansas Medical Center, Westwood
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/30更新 · NCT05382559First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
- University of Kansas Medical Center, Westwood
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/29更新 · NCT05875168Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Westwood Cancer Center, Westwood
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/29更新 · NCT05803382A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
- United Imaging Consultants, Lenexa
- MidAmerica Cancer Care- American Oncology Partners, Merriam
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06989437Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
- The University of Kansas Medical Center, Westwood
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/23更新 · NCT06915753A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- The University of Kansas Cancer Center - Westwood, Westwood
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/08更新 · NCT06119581Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- AMR Kansas City Oncology, Kansas City
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/02更新 · NCT06072612Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Cancer Center-Overland Park, Overland Park
- 他2件
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/31更新 · NCT05691491LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- University of Kansas Cancer Center, Westwood
被験者募集中第3相
18歳以上 · 全性別 · 2026/06/25更新 · NCT06216301Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- The University of Kansas Cancer Center, Westwood
被験者募集中第3相
18歳以上 · 全性別 · 2026/05/18更新 · NCT06757634A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
- University of Kansas Cancer Center, Westwood
被験者募集中第3相
18歳以上 · 全性別 · 2026/04/09更新 · NCT06064877A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
- The University of Kansas Cancer Center, Fairway
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/03/18更新 · NCT06244771Collection and Storage of Tissue and Blood Samples From Patients With Cancer
- Ascension Via Christi Hospitals Wichita, Wichita
- Cancer Center of Kansas - Wichita, Wichita
被験者募集中観察研究
2 Months · 全性別 · 2026/03/05更新 · NCT02474160A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
- Wichita Urology Group, Wichita
被験者募集中第1相
18歳以上 · 男性 · 2026/02/04更新 · NCT04729114ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。